In a report issued on July 30, Joshua Schimmer from Evercore ISI maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of $70.00. The company’s shares closed last Friday at $35.48.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 15.4% and a 53.3% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, 4D Molecular Therapeutics, and BioMarin Pharmaceutical.
COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $72.50, implying a 101.4% upside from current levels. In a report issued on July 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.
Based on COMPASS Pathways’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.72 million. In comparison, last year the company had a GAAP net loss of $8.59 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.